PMC:7127386 / 8942-9050 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"227","span":{"begin":12,"end":21},"obj":"Chemical"},{"id":"233","span":{"begin":56,"end":77},"obj":"Disease"}],"attributes":[{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"MESH:D000241"},{"id":"A233","pred":"tao:has_database_id","subj":"233","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T49","span":{"begin":49,"end":61},"obj":"Disease"},{"id":"T50","span":{"begin":62,"end":77},"obj":"Disease"},{"id":"T51","span":{"begin":68,"end":77},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0020502"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T53","span":{"begin":62,"end":67},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T130","span":{"begin":12,"end":21},"obj":"Chemical"}],"attributes":[{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_16335"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}

{"project":"LitCovid-sentences","denotations":[{"id":"T53","span":{"begin":0,"end":108},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":56,"end":61},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T244","span":{"begin":2,"end":6},"obj":"NCBITaxon:10633;CL_6"},{"id":"T245","span":{"begin":54,"end":63},"obj":"CHEBI:36357;CHEBI:36357"}],"text":"Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 \u003e100 100 \u003e100 \u003e100"}